Allogeneic stem cell transplantation for myelodysplastic syndromes: critical for cure? | Aplastic Anemia and MDS International Foundation

Allogeneic stem cell transplantation for myelodysplastic syndromes: critical for cure?

Journal Title: 
Clin Lymphoma Myeloma Leuk
Author(s): 
de Witte T
Primary Author: 
de Witte T
Original Publication Date: 
Saturday, June 11, 2011

Allogeneic stem cell transplantation (SCT) is the treatment of choice for young patients (age ≤ 55 years) with myelodysplastic syndromes (MDS) characterized by poor-risk or intermediate-risk cytogenetics, who have a histocompatible related or unrelated donor. For patients who lack an human leukocyte antigen-compatible donor, autologous SCT, or chemotherapy may be good alternatives for those with MDS and with good-risk cytogenetic characteristics. Iron toxicity is an underestimated cause of hematopoietic stem cell transplantation (HSCT) treatment-related mortality. The pathogenesis, diagnosis, and monitoring of iron-induced organ damage are currently topics of investigation. Prospective studies on the prevention or treatment of iron toxicity before HSCT and/or after HSCT are necessary.

Bone Marrow Diseases: